COMPLETE SPECIFICATION
APPLICANT: AKUMS DRUGS & PHARMACEUTICALS LTD. ADDRESS: 304, MOHAN PLACE,
LOCAL SHOPING COMPLEX, ABOVE STATE BANK OF INDIA, BLOCK-C, SARASWATI VIHAR, DELHI-110034, INDIA.
TITLE OF INVENTION: "AN INTRAVENOUS DRUG DELIVERY SYSTEM".
Field of Invention;
Filed of invention is related to the drug delivery system. More particulalry field is related to the pharamaceuical and Ciprofloxacin in combination formulation for the intravenous administration of a drug. Most particlaurly invention is related a pharmaceutical composition for intravenous administartion containing paracetamol and Ciprofloxacin in an aqueous base.
Background of the invention;
In pharmacology and toxicology, a route of administration is the path by which a drug, fluid, poison or other substance is brought into contact with the body. Obviously, a substance must be transported from the site of entry to the part of the body where its action is desired to take place (even if this only means penetration through the into the skin). However, using the body's transport
mechanisms for this purpose can be far from trivial. The pharmacokinetics properties of a drug (that is, those related to processes of uptake, distribution, and elimination) are critically influenced by the route of administration.
Routes of administration can broadly be divided into:
• topical: local effect, substance is applied directly where its action is desired
• enteral: desired effect is systemic (non-local), substance is given via the digestive route,
• parenteral: desired effect is systemic, substance is given by other routes than the digestive tract
Parenteral by injection;
• intravenous (into a vein), e.g. many drugs,
• intraarterial (into an artery), e.g. vasoloditor drugs in the treatment of vasospam and therobylotic drugs for treatment of embolisim,
• intramuscular (into muscle), e.g. many vaccines , antibiotics, and long-term psychoactive agents
• intracardiac (into the heart), e (no longer commonly performed)
• subcutaneous (under the skin), e.g. insulin
• intraosseous infusion (into the bone marrow) is, in effect, an indirect intravenous access because the bone marrow drains directly into the venous system. This route is occasionally used for drugs and fluids in emergency medicine and paediatrics when intravenous access is difficult.
• intradermal (into the skin itself) is used for skin testing some allergens and also for tattoos
• intrathecal (into the spinal canal) is most commonly used for spinal anesthesia and chemotherapy
Paracetamol or acetaminophen is a widely-used analgesic and antipyretic, Unlike aspirin it is not a very effective anti-inflammatory agent. It is well tolerated,
lacks many of the side-effects of aspirin and is available over-the-counter so it is commonly used for the relief of fever headaches, and other minor aches and pains. Paracetamol is also useful in the management of more severe pain, where it allows lower dosages of additional non-steroidal anti-inflammatory drugs (NSAIDs) to be used, thereby minimizing overall side-effects. It is also used in combination with opioid analgesics It is a major ingredient in numerous cold and flu medicationsintraperitoneal (infusion or injection into the peritoneum) e.g. peritoneal dialysis.
Ciprofloxacin is the generic international name for the synthetic antibiotic under the, e.g. Veterinary medicine, belonging to a group called fluoroquinolones. Ciprofloxacin is bacteriocidal Its mode of action depends upon blocking bacterial DNA replication by binding itself to an enzymz called DNA gyrase thereby causing double-stranded breaks in the bacterial chromosome.
Ciprofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase a type II topoisomerase which is an enzyme necessary to separate replicated DNA,the
eby inhibiting cell division. It is effective against:
Enterobacteriaceae
Vibrioz
Haemophilus influenzae
Haemophilus ducreyi
Neisseria gonorrhoeae (widespread resistance to ciprofloxacin limits its
usefulness in treating N. gonorrhea infections)
Neisseria meningitidis
Moraxella catarrhalis
Brucella
Campylobacter
Mycobacterium intracellulars
Legionella sp.
• Pseudomonas aeruginosa
• Bacillus ahthracis
• Escherichia coli
The major adverse effect seen with use is gastrointestinal irritation common with many antibiotics Because of its general safety, potency and broad spectrum activity, ciprofloxacin was initially reserved as a drug of last resort for use on difficult and antibiotic-resistant infections In cell culture it is used to treat infection with mycoplasma
Use against chlamydia and mycoplasma infections is now contraindicated; ciprofloxacin appears to be ineffective against these organisms, merely stopping their growth (and allowing them to resume growth after the antibiotic is withdrawn) rather than killing them,
Both patent and non patent litreture survey reveals,
United States Patent 7,179,849 discloses The present invention relates to antimicrobial compositions, methods for the production of these compositions, and use of these compositions with medical devices, such as catheters, and implants. The compositions of the present invention advantageously provide varying release kinetics for the active ions in the compositions due to the different water solubilities of the ions, allowing antimicrobial release profiles to be tailored for a given application and providing for sustained antimicrobial activity over time. More particularly, the invention relates to polymer compositions containing colloids comprised of salts of one or more oligodynamic metal, such as silver.
United States Patent 6,818,226 assignee to Acrux dds Pty. Ltd. (Victoria, AU) teaches about a transdermal drug delivery system which comprises at least one physiologically active agent or pro drug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one
physiologically active agent or pro drug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or pro drug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
United States Patent 6,787,157 discloses combination formulation comprising two or more active ingredients like a solid or semisolid, at least two-phase active ingredient-containing formulation in which there is multi particulate incorporation of one of the two phases into a matrix of the other phase, and at least one of the phases contains at least one active ingredient, obtainable by introducing particles of one phase into the other phase in a plastic state, and shaping the material while still plastic.
Object of the invention;
An object of the invetion is to design a direct injection method for the paracetamol and Ciprofloxacin. Another object of the invention is to formulate intraveous formulation of the paracetamol and Ciprofloxacin in comibation. Yet another object of the invention is to prepare water based formulation of intravenous adminstration of the paracetamol and ciprofloxacin.
Summary of the invention;
Present invention is related to intravenous administration of the paracetamol and Ciprofloxacin in combination. In this method paracetamol powder and
iprofloxacin are dissolved seperatly in the aquesous phase and suitable pH is adjusted by acid or base and this solution is direcly administered in the patients body though the direct injection.
The advantages of the direct delivery of the combination in to blood flow and immediate relief form the suffering.
Detailed Description of the invention;
The subject in the methods described herein can be, e.g., a mammal, e.g., a human, mouse, rat, dog, cat, horse, cow, pig, or non-human primate. In some embodiments, the subject is a juvenile human, e.g., a subject less than 7 years of age.
The term "pharmacologically effective amount" as used herein means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
Administration to the subject in the methods described herein can be, e.g., intravenous, intramuscular, subcutaneous, sublingual, oral, rectal or via aerosol delivery. The compositions are preferably suitable for internal use and include an effective amount of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers. The compounds are especially useful in that they have very low, if any, toxicity.
The method of administration of the paracetamol and Ciprofloxacin in the present invention is through the intravenous route through an aqueous vehicle. The paracetamol and Ciprofloxacin is dissolved in water for injection separately. The injection thus prepared also contains adjuvants, buffers isotonic.
Adjuvants are pharmacological or immunologicalagents that modify the effect of other agents (e.g., drugs, vaccines) while having few if any direct effects when given by themselves. In this sense, they are roughly analogous to chemical.
Phosphate buffered saline (abbreviated PBS) is a buffer solution commonly used in biochemistry and other branches of biological research. It is a salty solution containing sodium chloride and (in some formulations) sodium chloride and potassium dihydrogen phospahte . The buffer helps to maintain a constant pH The osmolarity and ion cone
Potassium hydrogen phthalate, often called simply KHP, is a white or colorless, ionic solid that is the monopotassium salt of phthalic acid.The hydrogen is slightly acidic, and it is often used as a primary standard for acid-base titrations because it is solid and air-stable, making it easy to weigh accurately. It is, however, slightly hygroscopic and is generally kept in a desiccator before use. It is also used as a primary standard for calibrating pH meters because, besides the properties just mentioned, its pH in solution is very stable.
KHP can be used as a buffering agent (in combination with HCI or NaOH depending on which side of pH 4.0 the buffer is to be) but should not be used as a buffer for decarboxylation reactions, as these will degrade the KHP and mop up the conjugation groups
Stability of the aqueous solutions mentioned above does not solely depend on the choice of a given carrier. It also depends on other variables, such as careful adjustment of pH, removal of oxygen dissolved in the carrier and addition of a free radical antagonist or a free radical scavenger.
Removal of dissolved oxygen is readily accomplished by bubbling an inert gas and preferably by bubbling nitrogen.
Preferred ascorbic acid derivatives are D- or L-ascorbic acid, an alkali metal ascorbate, an alkaline earth metal ascorbate or even still an aqueous medium-soluble ascorbic acid ester.
The polyol used as a free radical scavenger is preferably a straight chain or a cyclic, polyhydroxy alcohol such as mannitol, sorbitol, inositol, isosorbide, glycerol, glucose and propylene-glycols.
Among free radical scavengers required pour stabilizing paracetamol, the ascorbic acid derivative currently preferred is sodium ascorbate. Preferred thiol functional group substituted derivatives are cystein, reduced-slate glutathion, N-acetylcystein and mercaptoethane sulfonic acid.
It may appear as convenient to combine several free radical scavengers as far as they are water-soluble and mutually compatible. Especially convenient free radical scavengers are mannitol, glucose, sorbitol or even glycerol. These may be readily combined.
It may appear as convenient to add to the preparation one or a number of complexing agents to improve stability of the molecule since the active ingredient is sensitive to the presence of trace metals that eventually speed up its decay. Sodium chloride, also known as common salt, table salt, or halite is a chemical compound with the formula Sodium chloride is the salt most responsible for the salinity.
The gas that is bubbled into the solution to drive out oxygen may be nitrogen or carbon dioxide or still an inert gas. Nitrogen is favoured.
Isotonicity of the preparation may be achieved by adding an appropriate quantity of sodium chloride, glucose, levulose or postassium chloride, or calcium chloride,
or calcium gluconoglucoheptonate, or mixtures thereof. The preferred isotonizing agent is sodium chloride.
The buffer used is a buffer compatible with parenteral administration in humans, the pH of which may be adjusted between 4 and 8. Preferred buffers are based on alkali metal alkaline earth metal acetates or phosphates. A more preferred buffer is sodium acetate/hydrogene phosphate adjusted to the required pH with hydrochloric acid or sodium hydroxide. The concentration of such a buffer may be comprised between 0.1 and 10 mg/ml. The preferred concentration is confined in the range of 0.25 to 5 mg/ml.
On the other hand, preparations for injection have to be sterile and should lend themselves to heat treatment sterilization. It is known that in certain conditions, antioxidants such as glutathion are broken down jFIALAIRC A. et al., J. Pharm. Biomed. Anal., vol. 10, No 6, pp. 457-460 (1992)]. The breakdown of reduced glutathion during heat treatment sterilization ranges from 40 to 77% depending on the selected temperature conditions. During such sterilization procedures, it is convenient to employ means capable of preserving the integrity of these antioxidants. Addition of complexing agents to aqueous solutions inhibits thermal decomposition of thiol derivatives, such as glutathion, edentate sodium.
During such sterilization procedures, it is convenient to employ means capable of preserving the integrity of these antioxidants. Addition of complexing agents to aqueous solutions inhibits thermal decomposition of thiol derivatives, such as glutathion, Disodium edetate.
Liquid pharmaceutical compositions according to the invention are preferably compositions intended for injection. The paracetamol content of the solution may range from 2 mg/ml to 50 mg/ml in case of so called dilute solutions, i.e. that can be directly infused by intravenous route and from 60 mg/ml to 350 mg/ml where so-called concentrated solution are considered, i.e. either intended for direct injection by intravenous or intramuscular route, or intended to be diluted prior to
slow infusion administration. The preferred concentration are comprised between 5 and 20 mg/ml for dilute solutions and between 100 and 250 mg/ml for concentrated solutions or mostly the amount which is pharmaceutically effective amount is used for the preparation of the said formulation.
Pharmaceutical compositions according to the invention may further contain
another active ingredient that enhances the specific effect of paracetamol and
Ciprofloxacin.
The term isotonic may refer to;
• Isotonic muscle exercise
• Isotonic (exercise physiology) for the term associated with muscle contraction
• solutions that have equal osmotic pressure, such as the isotonic environment in cell biology
• to assist athletes rehydrate while balancing electrolytes
Concentration of the solution usually match those of the human body (isotonic). The process is carried at the different temperatures. The activity increases after the direct administration of the combination of paracetamol and ofloxacin so that patient get immediate relief.
Method followed for the preparation of the combination formulation is dissolving paracetamol and ofloxacin seperatly in 0.1 N HCI. Foolowed by an addtion of the dosodium edetate and sodium chloride. pH of the mixture mixture is adjusted to 6.5-7.2 by using acid-base combination. Here in the present invention this is HCI-NaOH. The desired volume is achived by using degassed and sterlized water.
Examples
Paracetamol 50-500 mg Ciprofloxacin 50-500 mg
Sodium hydrogen 0.0025 g 0.00025 g 000025 g
phosphate dihydrate 0.002 g
Sodium chloride 0.002 g 0002 g
Disodium ethylene 0.0001 g 0.0001 g 0.0001 g Hydrochloric acid or q.s. pH 7.0 q.s. pH 7.5 q.s
Sodium hydroxide
Water for injection q.s.f. 1000 ml q.s.f. 1000 ml q.s.f. 1000 ml Nitrogen q.s.f. bubbling q.s.f

I/WE Claims:
1. An intravenous drug delivery system comprising;
(a) water;
(b) pharamaceitically aceptable adjuvants, excipients,chelating agents,
(c) isotonic soution /buffer solution,
(d) pharmaceitically effectve amount of active ingridents,
wherein, water used for the said system is purged with nitrogen gas to remove dissolved gases form the water. •
2. An intravenous drug delivary system accodring to claim 1 wherein water is 1.0-1000 ml.
3. An intravenous drug delivary system accodring to claim 1 wherein isotonic soution /buffer solution is phosphate buffer, sodium phospahte dibasic anhyrdous, sodium chloride, complexing agent is disodium edetate.
4. An intravenous drug delivery system accodring to claim 1 wherein active ingridents are paracetamol and ciprofloxacin.
5. A method for preparation of intravenous drug delivery system comrising;

(a) purging nitrogen gas thorugh water,
(b) dissolving pharamaceutically effective amount of the paracetamol and ciprofloxacin seperatly in 0.1 N HCI,
(c) addtion of appropriate amount of sodium phospahte dibasic anhydrous, sodium chloride, sodium sulphaite,
(d) adjusting pH 3.7-4.2 by using acid or base;
(e) making up volume with the sterlized degassed water.
6. An intravenous drug delivary system as described with refrence to
description and example herein.